Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00380900 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00380900 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer.
The verdict
NCT00380900, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of this study is to evaluate the safety and tolerbility of ascending multiple oral doses of AGG-523 in healthy subjects and in subjects with osteoarthritis.
Interventions
- DRUG AGG-523
Trial Details
| Field | Value |
|---|---|
| Start Date | 2006-07 |
| Est. Completion | 2007-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00380900
The ClinicalTrials.gov registry entry for NCT00380900 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AGG-523 is the first listed.
NCT00380900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00380900 about?
NCT00380900 is a clinical study titled "Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy". The purpose of this study is to evaluate the safety and tolerbility of ascending multiple oral doses of AGG-523 in healthy subjects and in subjects with osteoarthritis.
What is the current status of trial NCT00380900?
This trial is currently completed. It is a Phase 1 study. The study started on 2006-07. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00380900?
The interventions under investigation include: AGG-523 (DRUG).
Who is sponsoring clinical trial NCT00380900?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.